Ramesh K Ramanathan
Overview
Explore the profile of Ramesh K Ramanathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
179
Citations
10903
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jameson G, Borazanci E, Babiker H, Poplin E, Niewiarowska A, Gordon M, et al.
JAMA Oncol
. 2019 Oct;
6(1):125-132.
PMID: 31580386
Importance: Genomes of metastatic pancreatic cancers frequently contain intrachromosomal aberrations, indicating a DNA repair deficiency associated with sensitivity to DNA damaging agents, such as platinum. Objective: To determine response rate...
12.
Gorbunova V, Beck J, Hofheinz R, Garcia-Alfonso P, Nechaeva M, Gracian A, et al.
Br J Cancer
. 2019 Jul;
121(5):429-430.
PMID: 31350526
The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read "65"...
13.
Shroff R, Javle M, Xiao L, Kaseb A, Varadhachary G, Wolff R, et al.
JAMA Oncol
. 2019 Apr;
5(6):824-830.
PMID: 30998813
Importance: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering...
14.
Ramanathan R, Thomas G, Khorana A, Shah S, Zhou C, Wong S, et al.
Oncology
. 2019 Mar;
96(4):217-222.
PMID: 30844808
Objectives: Tissue factor overexpression is associated with tumor progression, venous thromboembolism, and worsened survival in patients with cancer. Tissue factor and activated factor VII (FVIIa) complex may contribute to tumor...
15.
Lee J, Stone M, Porrett P, Thomas S, Komar C, Li J, et al.
Nature
. 2019 Mar;
567(7747):249-252.
PMID: 30842658
The liver is the most common site of metastatic disease. Although this metastatic tropism may reflect the mechanical trapping of circulating tumour cells, liver metastasis is also dependent, at least...
16.
Ramanathan R, McDonough S, Philip P, Hingorani S, Lacy J, Kortmansky J, et al.
J Clin Oncol
. 2019 Mar;
37(13):1062-1069.
PMID: 30817250
Purpose: Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin...
17.
Egan J, Marks D, Hogenson T, Vrabel A, Sigafoos A, Tolosa E, et al.
JCO Precis Oncol
. 2019 Feb;
2017.
PMID: 30761385
Purpose: Genomic testing has increased the quantity of information available to oncologists. Unfortunately, many identified sequence alterations are variants of unknown significance (VUSs), which thus limit the clinician's ability to...
18.
Gorbunova V, Beck J, Hofheinz R, Garcia-Alfonso P, Nechaeva M, Gracian A, et al.
Br J Cancer
. 2018 Dec;
120(2):183-189.
PMID: 30531832
Background: Metastatic colorectal cancer (mCRC) has low survival rates. We assessed if addition of veliparib, concurrent to FOLFIRI, improves survival in patients with previously untreated mCRC. Methods: This study compared...
19.
Strickler J, Weekes C, Nemunaitis J, Ramanathan R, Heist R, Morgensztern D, et al.
J Clin Oncol
. 2018 Oct;
36(33):3298-3306.
PMID: 30285518
Purpose: This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug conjugate of the anti-c-Met monoclonal antibody ABT-700 and monomethyl auristatin E. Materials And Methods: For dose escalation,...
20.
Deleon T, Zhou Y, Nagalo B, Yokoda R, Ahn D, Ramanathan R, et al.
Immunotherapy
. 2018 Sep;
10(12):1077-1091.
PMID: 30185133
Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but...